Compile Data Set for Download or QSAR
maximum 50k data
Found 110 Enz. Inhib. hit(s) with all data for entry = 754
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159970(US10093663, Example 20a | US9682968, Example-20a)
Affinity DataIC50:  9nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289502(US10093663, Example 27-4a)
Affinity DataIC50:  9nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160475(US10093663, Example 26b | US9682968, Example-26a)
Affinity DataIC50:  10nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159938(US10093663, Example 17-29 | US9682968, Example-17-...)
Affinity DataIC50:  11nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159545(US10093663, Example 17-30 | US9682968, Example-17-...)
Affinity DataIC50:  13nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289488(US10093663, Example 22-2b)
Affinity DataIC50:  13nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289500(US10093663, Example 27-3a)
Affinity DataIC50:  14nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159486(US10093663, Example 17-11 | US9682968, Example-17-...)
Affinity DataIC50:  15nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289498(US10093663, Example 27-2a)
Affinity DataIC50:  15nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159312(US10093663, Example 17-1 | US9682968, Example-17-1)
Affinity DataIC50:  19nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289485(US10093663, Example 22-1a)
Affinity DataIC50:  19nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160036(US10093663, Example 21a | US9682968, Example-21a)
Affinity DataIC50:  19nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160499(US10093663, Example 36 | US9682968, Example-36)
Affinity DataIC50:  20nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160500(US10093663, Example 37 | US9682968, Example-37)
Affinity DataIC50:  22nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289497(US10093663, Example 27-1b)
Affinity DataIC50:  22nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159545(US10093663, Example 17-30 | US9682968, Example-17-...)
Affinity DataIC50:  23nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159566(US10093663, Example 17-18 | US9682968, Example-17-...)
Affinity DataIC50:  27nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159311(US10093663, Example 16 | US9682968, Example-16)
Affinity DataIC50:  30nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289450(US10093663, Example 17-2 | US10093663, Example 17-...)
Affinity DataIC50:  30nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159873(US10093663, Example 17-24 | US9682968, Example-17-...)
Affinity DataIC50:  35nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159289(US10093663, Example 5-12 | US9682968, Example-5-12)
Affinity DataIC50:  37nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289451(US10093663, Example 17-3)
Affinity DataIC50:  38nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159920(US10093663, Example 17-25 | US9682968, Example-17-...)
Affinity DataIC50:  45nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160473(US10093663, Example 25b | US9682968, Example-25a (...)
Affinity DataIC50:  47nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160506(US10093663, Example 40 | US9682968, Example-40)
Affinity DataIC50:  55nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159509(US10093663, Example 17-13 | US9682968, Example-17-...)
Affinity DataIC50:  63nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159379(US10093663, Example 17-8 | US9682968, Example-17-8)
Affinity DataIC50:  70nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289452(US10093663, Example 17-4)
Affinity DataIC50:  87nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159841(US10093663, Example 17-22 | US9682968, Example-17-...)
Affinity DataIC50:  100nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159382(US10093663, Example 17-10 | US9682968, Example-17-...)
Affinity DataIC50:  100nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289450(US10093663, Example 17-2 | US10093663, Example 17-...)
Affinity DataIC50:  120nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160501(US10093663, Example 38 | US9682968, Example-38)
Affinity DataIC50:  130nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159303(US10093663, Example 13 | US9682968, Example-13)
Affinity DataIC50:  140nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159932(US10093663, Example 17-28 | US9682968, Example-17-...)
Affinity DataIC50:  160nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289524(Ethyl 4-((2S,4R)-1-((5-methoxy-7-methyl-1H-indol-4...)
Affinity DataIC50:  165nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159157(US10093663, Example 5-4 | US9682968, Example-5-4)
Affinity DataIC50:  180nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159302(US10093663, Example 12 | US9682968, Example-12)
Affinity DataIC50:  230nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160508(US10093663, Example 42 | US9682968, Example-42)
Affinity DataIC50:  240nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160504(US10093663, Example 39-3 | US9682968, Example-39-3)
Affinity DataIC50:  280nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159976(US10093663, Example 20b | US9682968, Example-20b)
Affinity DataIC50:  290nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160505(US10093663, Example 39-4 | US9682968, Example-39-4)
Affinity DataIC50:  300nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160495(US10093663, Example 32-3 | US9682968, Example-32-3)
Affinity DataIC50:  340nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159506(US10093663, Example 17-12 | US9682968, Example-17-...)
Affinity DataIC50:  450nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159296(US10093663, Example 9-2 | US9682968, Example-9-2)
Affinity DataIC50:  640nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160051(US10093663, Example 21b | US9682968, Example-21b)
Affinity DataIC50:  650nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159184(US10093663, Example 5-6 | US9682968, Example-5-6)
Affinity DataIC50:  660nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159294(US10093663, Example 8 | US9682968, Example-8)
Affinity DataIC50:  710nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159102(US10093663, Example 4b | US9682968, Example-3)
Affinity DataIC50:  720nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM289501(US10093663, Example 27-3b)
Affinity DataIC50:  740nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM159840(US10093663, Example 17-21 | US9682968, Example-17-...)
Affinity DataIC50:  840nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 110 total ) | Next | Last >>
Jump to: